Profound Medical raises $8m for urology, women’s health devices

Profound Medical (TSX:PRN) said today that it inked an $8 million “bought” deal” financing with a pair of underwriters that it plans to use for its Tulsa-Pro and Sonalleve ablation devices.

The funding, by Echelon Wealth Partners and  CIBC Capital Markets, involved 10 million units at 80¢ (C$1 ) apiece, consisting of a stock share and a half of a 36-month warrant priced at $1.12 (C$1.40), the Toronto-based company said. The deal also includes a 30-day over-allotment option for another 1.5 million shares, which if exercised would push the gross proceeds to $9.2 million (C$11.5 million).

Profound said it plans to use the proceeds to cover clinical work for the Tulsa-Pro MR-guided prostate ablation treatment and the Sonalleve MR-HIFU device for treating uterine fibroids and bone metastases.

Earlier this month, Profound closed its $6 million acquisition of the Sonalleve device from Royal Philips (NYSE:PHG). The company raised $13.2 million late last year.

($1 = C$1.25018)

The post Profound Medical raises $8m for urology, women’s health devices appeared first on MassDevice.

from MassDevice http://ift.tt/2vn1R6u